论文部分内容阅读
目的:观察基础胰岛素联合口服降糖药物临床应用有效性及安全性。方法:选择120例应用口服降糖药物治疗但血糖控制不佳(Hb A1c>7.0%)2型糖尿病患者,随机分为两组,分别加用基础胰岛素(甘精胰岛素或地特胰岛素)和预混胰岛素(诺和灵30R或甘舒霖30R)治疗,24周后,观察FBG、2h PG、Hb A1c达标率及低血糖发生率、BMI变化评价方案有效性及安全性,采用问卷调查评分比较满意度。结果:两组患者治疗24周后,FBG、2h PG、Hb A1c水平较治疗前明显降低(P<0.05),而两组间FBG、2h PG、Hb A1c达标率有统计学差异(P<0.05),两组间低血糖发生率有统计学差异(P>0.05),两组间BMI变化无统计学差异(P<0.05),患者对治疗满意度有统计学差异(P>0.05)。结论:应用基础胰岛素联合降糖药物治疗口服降糖药物血糖控制不佳的2型糖尿病患者其安全性、有效性优于预混胰岛素联合口服药物。
Objective: To observe the clinical efficacy and safety of basic insulin combined with oral hypoglycemic agents. Methods: A total of 120 patients with type 2 diabetes who were treated with oral hypoglycemic drugs but had poor blood glucose control (Hb A1c> 7.0%) were randomly divided into two groups. The patients were treated with basal insulin (insulin glargine or insulin detemir) 24 hours later, the compliance rates of FBG, 2h PG and Hb A1c, the incidence of hypoglycemia, the effectiveness and safety of BMI changes were evaluated, and the satisfaction of questionnaire survey was compared . Results: The FBG, 2h PG and Hb A1c levels in two groups were significantly lower than those before treatment (P <0.05) after 24 weeks of treatment, but there was significant difference between the two groups (P <0.05 ). There was a significant difference in the incidence of hypoglycemia between the two groups (P> 0.05). There was no significant difference in BMI between the two groups (P <0.05). There was a statistically significant difference in satisfaction between the two groups (P> 0.05). CONCLUSIONS: The safety and efficacy of basal insulin combined with hypoglycemic agents in the treatment of patients with type 2 diabetes with poor glycemic control by oral hypoglycemic agents is superior to premixed insulin plus oral drugs.